TirzepatideYog tus tshiab dual receptor agonist uas ua tiav cov kab mob qab zib thiab cov roj ntsha ua kom zoo li peptide {}}}}}}} 1 (GLP-1) receptor. Nws cov tshuab kev nqis tes ua kecompasses ntau yam xws li glucagon nchuav, thiab kev txhim kho ntawm cov metabolism hauv lub zog, ua kom muaj cov nyhuv zoo sib xws. Cov kev ntsuas hauv qab no yog ua los ntawm peb yam: molecular txheej txheem, cov ntshav qab zib kev cai kev cai, thiab poob phaus nyhuv.
|
|
|
|
|
|
|
|
Molecular txheej txheem: Tus qauv tsim tshwj xeeb ntawm ob lub tshuab txais
The molecular structure of Tirzepatide consists of 39 amino acids and is modified with C20 fatty acid to bind with albumin, significantly extending its half-life to 5 days, which supports a once-weekly subcutaneous injection regimen. Cov tub ntxhais kev hloov pauv dag nyob hauv ib txhij zuj zus ob qho tib si gip thiab GLP-1 cov khoom siv, raws li ob lub recepors ua si tau cov kev cai zoo li no:
Gip receptor:Feem ntau faib rau hauv cov hlwb pancreatic, cov ntaub ntawv adipose, thiab cov leeg ntshav hauv nruab nrab. Kev ua kom tau txais kev txhawb nqa insulin zais (tshwj xeeb tshaj yog nyob rau hauv thawj -} paim gluctake los ntawm cov roj ntsha thiab txo cov kev tso tawm ntawm cov roj fatty.
GLP-1 tus nqi muag:Dav faib tawm hauv cov txiav, cov plab zom mov, thiab lub hlwb lub chaw so. Kev ua kom tsis txhob tsuas yog ua rau muaj kev tso pa tawm insulin tab sis kuj tso tawm glucagon tso tawm, qeeb glumicing, thiab transmitts singiety qhia los ntawm nruab nrab lub paj hlwb.
Tsoos GLP-1 Cov Kev Tshawb Fawb Txog Kev Ua Haujlwm (xws li semaglutide) tsuas qhib ib txoj hauv kev ua tiav cov kev cai metabolic muaj zog ". Piv txwv li, ua kom muaj kev tiv thaiv gip ntau dhau los ntawm GLP-1 tus receptor cov glucagon muaj zog, thiab ua tib lub sijhawm txhim kho insulin zais cia rhiab.
Ntshav Qab Zib Cov Kev Cai Koom Tes Ua Si: Zov -}} link link link link້ນ sib koom tes tswj kev tswj hwm
Tirzepatide ua tiav cov lus qhia txog qab zib zoo los ntawm txoj hauv kev hauv qab no:
Txhim kho cov kuazhee - kav cov pa luam yeeb
Phase 1 Daim ntawv tso cov ntawv tso tawm: Tom qab noj mov, theem gip thiab glp {{}} 1 tso tawm los ntawm txoj hnyuv sawv sai. Tirzepatide mimics Cov txheej txheem no thiab txhawb kev ua kom zoo dua ntawm cov kabmob hauv pancer (theem 1
Phase 2 secretion persistence: By continuously activating the GIP and GLP-1 receptors, Tirzepatide prolongs the duration of insulin secretion (phase 2 secretion), ensuring the long-term stability of post-meal blood sugar.
Inhibition ntawm glucagon secachion
GLP-1 rov qab rominance: Ua kom muaj txiaj ntsig ntawm GLP-1 tau rov qab mus ncaj qha rau ntawm glucagon los ntawm bancatic cov kua dej thiab txo hepatic qabzed tso zis tawm.
Kev tswj cov nyhuv ntawm GIP Receptors: txawm tias GIP tuaj yeem ua kom zoo dua cov tshuaj thiab lub sijhawm ua kom zoo dua qub, ua rau nws lub sijhawm ua kom zoo dua qub Piv txwv li, hauv kev hypoglycemic xeev, ua kom cov gip receptors yuav xum txhawb gluuconogenesis kom tswj hwm ntshav qab zib nrog glp-1 receptors rau inhibit glucagon.
Ncua lub plab zom mov nchuav thiab qab los noj mov
Hnoos cov kev ua kom muaj txoj cai: Ua kom ua kom lub GLP- 1 recepong lub sij hawm nqus tau thiab txo lub ncov ntawm cov kab mob post-flue Ntshav Qab Zib.
Central ntshav cov kev cai: tirzepatide activ kev ua kom zoo nkauj, zoo li kev tso tawm ntawm Corticotropin-tso cov khoom noj), txo cov zaub mov noj. Kev ua kom muaj zog ntawm GIP Receptors yuav ua rau muaj kev ua yeeb yam ntxiv los ntawm kev txhim kho qhov nruab nrab nyhuv ntawm GLP-1 receptors.
Txhim kho cov tshuaj insulin rhiab
Kev ua kom zoo ntawm cov nqaij me metabolism: Ua kom muaj cov roj ntsha ua kom muaj roj ua kua qaub thiab cov ntaub so ntswg ua kom tawv nqaij thiab mob taub hau
Kev txiav txim siab rau lub siab ua haujlwm: Tirzepatide inhibits cov kev qhia ntawm daim siab gluboxyinedes), txo cov kev xav tau ntawm daim siab ntawm daim siab rau insulin.
Lub cev poob phaus: dual drive ntawm cov ntshav qab zib thiab lub zog sib npaug
Qhov poob phaus nyhuv ntawm tirzepatide yog qhov tshwm sim ntawm kev sib xyaw ntawm cov ntshav qab zib ntawm cov kev cai ntawm cov ntshav thiab lub zog sib npaug, thiab nws cov tshuab sib npaug tau muab cov ntsiab lus sib xws tau ua hauv qab no:
Txo cov calorie
Kev noj qab haus huv ncaj qha Kev: Los ntawm kev nqis tes ua ntawm lub plawv nruab nrab, tirzepatide tau txo qis kev tshaib plab thiab tsawg txhua hnub. Cov kev tshawb fawb soj ntsuam tau qhia tias cov neeg mob muaj qhov txo qis ntawm 500-700 kilocaliories hauv ib hnub, thiab cov nyhuv no rau cov sij hawm ntev.
Kev hloov pauv hauv cov khoom noj khoom noj: Tirzepatide yuav txo qhov muaj siab rau high {} cov khoom noj muaj roj ntawm lub hlwb cov nqi zog (xws li cov kev xaiv noj qab haus huv.
Nce Zog Siv Tau Zog
Kev ua kom muaj rog cov nqaij metabolism: Ua kom muaj kev ua haujlwm ntawm cov roj av dawb rau cov roj av dawb (paub tias yog "browning"), yog li nce cov theem ntawm metabolic.
Kev ua kom zoo ntawm cov leeg hluav taws xob siv: tirzepatide txhim kho cov insulin rhiab heev insulin rhiab heev ntawm cov dej qab zib thiab siv cov txiaj ntsig zoo, thiab txo cov teeb meem pov tseg, thiab txo cov piam thaj, thiab txo cov teeb meem pov hwm hluav taws xob.
Txhim kho hauv cov rog faib
Txo cov roj av visceral tau qhia tias Tirzepatide tuaj yeem txo thaj tsam visceral thiab txhim kho cov tsos mob muaj rog. Qhov no yuav cuam tshuam nrog nws kev cuam tshuam ntawm daim siab lipid synthesis thiab txhawb nqa cov rog roj plab oxidation.
Rov qab kho cov roj subcutaneous: los ntawm kev tswj hwm cov roj ntsha thiab apoptoses propotes rog ntawm cov roj sib txuam hauv zos (xws li hauv plab thiab pob tw).
Mechanism ntawm Kev Txij Nkawm
Cov teeb tsa kev hloov kho ntawm cov tshuaj tsis zoo: Cov khoom siv yuag feem ntau ua rau muaj kev sib txuam ntawm cov khoom siv hluav taws xob (xws li kev sib npaug
Cov kev cai ntawm cov qib Hormones: ntev - kev siv cov tshuaj sormones thiab nce ntxiv peptide-2), tsim ib puag ncig ntawm ib puag ncig.
Cov Txiaj Ntsig Ua Pov Thawj: Dual ntawm cov ntshav qab zib thiab qhov hnyav
Ntau theem III chaw kuaj mob (xws li cov surpeem surpass) tau lees tias qhov tseem ceeb ua tau zoo ntawm tirzepatide cov cai kev cai thiab poob phaus:
Ntshav ntshav qab zib:Tom qab 52 lub lim tiam ntawm kev kho nrog tirzepatide hauv cov neeg mob ntshav qab zib femoglobin (HBA1C), xws li insulin glargine, semaglowside).
Poob phaus:Tom qab 72 lub lis piam ntawm kev kho nrog tirzepatide nyob rau hauv cov rog lossis rog dhau, qhov hnyav nruab nrab poob los ntawm 14.9% rau 20.9%. Nyob rau hauv cov pab pawg koob ntau tshaj plaws (15mg), ntau dua 50% ntawm cov neeg mob uas muaj kev poob phaus ntawm ntau tshaj 20%.
Metabolic Syndrome Kev Txhim Kho:Tirzepatide tuaj yeem txo qis cov ntshav siab thiab lipid qib (qis} {{{{-}}}}} roj cawv rog.
Xaus: Lub Cim Tshiab ntawm Dual Receptor Synergy
Tirzepatide ua tiav cov hom phiaj ntshav thiab poob phaus los ntawm ib txhij ua kom lub gip thiab glp {} 1 receptors. Nws lub tshuab tsis yog suav nrog kev txhim kho insulin tsis zoo, tab sis kuj tseem ua kom zoo dua cov rog rog, thiab tseem noj qab haus huv kev cai lij choj This multi-target synergy enables Tirzepatide to demonstrate significant advantages in efficacy (especially weight loss) and safety (such as low risk of hypoglycemia), providing a revolutionary solution for the treatment of type 2 diabetes and obesity. Kev tshawb fawb yav tom ntej yuav tsum tau los tshawb ntxiv nws cov kev cuam tshuam ntev thiab cov tshuaj kho mob rau cov kev kho mob kom ua tau cov txiaj ntsig kev kho mob.